The guanylate cyclase stimulator vericiguat: Insights and adverse events from a FAERS-based pharmacovigilance study

Our analysis provides a comprehensive safety assessment of vericiguat. Most of these results align with findings from previous studies. In addition, our data revealed several new adverse events. This study provides valuable insights that can inform future research and clinical practice.